Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. INTC
2. DSX
3. GNK
4. AWK
5. SPCX
6. III
7. TTEC
8. DAL
9. INDB
10. ERAS

Go back to Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Catalyst Pharmaceuticals (CPRX) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY25 Revenue Guidance

February 26, 2025 4:24 PM EST

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.70, $0.38 better than the analyst estimate of $0.32. Revenue for the quarter came in at $141.8 million versus the consensus estimate of $133.68 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2025 revenue of $545-565 million, versus the consensus of... More